Kathiawad Today

Hepatocellular Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

 Breaking News
  • No posts were found

Hepatocellular Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

March 13
20:20 2023
Hepatocellular Carcinoma Pipeline Assets and Comparative Analysis of Clinical and Non-Clinical Stage Products

DelveInsight’s, “Hepatocellular Carcinoma Pipeline Insight 2023” report provides comprehensive insights about 80+ companies and 80+ pipeline drugs in the Hepatocellular Carcinoma pipeline landscape. It covers the Hepatocellular Carcinoma pipeline drug profiles, including Hepatocellular Carcinoma clinical trials and nonclinical stage products. It also covers the Hepatocellular Carcinoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

For Hepatocellular Carcinoma Emerging drugs, the Hepatocellular Carcinoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Hepatocellular Carcinoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

 

In the Hepatocellular Carcinoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Hepatocellular Carcinoma clinical trials studies, Hepatocellular Carcinoma NDA approvals (if any), and product development activities comprising the technology, Hepatocellular Carcinoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

Key takeaways from the Hepatocellular Carcinoma Pipeline Report

 

  • DelveInsight’s Hepatocellular Carcinoma Pipeline report depicts a robust space with 80+ active players working to develop 80+ pipeline therapies for Hepatocellular Carcinoma.

 

  • The leading Hepatocellular Carcinoma Companies such as Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals,  Akeso Biopharma, Innovent Biologics, Eli Lilly and Company, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Jiangsu Hengrui Medicine, Shenogen Pharma, and others.

 

  • Promising Hepatocellular Carcinoma Pipeline therapies such as lenvatinib, pembrolizumab (200 mg), Tivozanib, Durvalumab, Sorafenib, Enzalutamide, AZD9150, GC33 (RO5137382), mapatumumab, and others.

 

  • The Hepatocellular Carcinoma Companies and academics are working to assess challenges and seek opportunities that could influence Hepatocellular Carcinoma R&D. The Hepatocellular Carcinoma pipeline therapies under development are focused on novel approaches to treat/improve Hepatocellular Carcinoma. 

 

Request a sample and discover the recent breakthroughs happening in the Hepatocellular Carcinoma Pipeline landscape @ Hepatocellular Carcinoma Pipeline Outlook Report

 

Hepatocellular Carcinoma Overview

Hepatocellular carcinoma (HCC) is a rare disorder in the United States, but the most common primary tumor of the liver. Most people have an underlying liver disease such as infection with hepatitis B or C virus, or non-alcoholic fatty liver disease. Most people have cirrhosis, which is scarring of the liver that can occur as a result of chronic liver diseases. If HCC is found early, there may be curative treatments offered. However, HCC often does not cause any symptoms, especially early in the disease course. If HCC is diagnosed at a late stage, patients may not be able to receive curative treatments, and care is then geared toward helping people have a better quality of life. Although HCC does not necessarily cause symptoms, many individuals will have symptoms caused by the underlying liver disease. The exact cause of HCC is not fully understood. Most people do not have any noticeable symptoms associated with hepatocellular carcinoma.

 

Recent Developmental Activities of Hepatocellular Carcinoma Treatment Landscape

 

  • SCT I10A is a drug used to treat Hepatocellular Carcinoma. SCT I10A is being actively studied in II/III study; no studies for this drug have been completed so far.

 

  • FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies.

 

  • FOTIVDA was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma for the treatment of adult patients with advanced RCC. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Tivozanib was discovered by Kyowa Kirin (KKC) and is also being studied as a new formulation by KKC in wet acute macular degeneration.

  

For further information, refer to the detailed Hepatocellular Carcinoma Drugs Launch, Hepatocellular Carcinoma Developmental Activities, and Hepatocellular Carcinoma News, click here for Hepatocellular Carcinoma Ongoing Clinical Trial Analysis

 

Hepatocellular Carcinoma Emerging Drugs Profile

 

  • Tivozanib: AVEO Oncology

FOTIVDA® (tivozanib) is an oral, once-daily, differentiated vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor (TKI). It is a potent, selective inhibitor of VEGFRs 1, 2, and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) following two or more prior systemic therapies. FOTIVDA was approved in August 2017 in the European Union and other countries in the territory of its partner EUSA Pharma for the treatment of adult patients with advanced RCC. Tivozanib has been shown to significantly reduce regulatory T-cell production in preclinical models. Tivozanib was discovered by Kyowa Kirin (KKC) and is also being studied as a new formulation by KKC in wet acute macular degeneration.

 

  • SCT-I10A: Sinocelltech

SCT I10A is a drug used to treat Hepatocellular Carcinoma. SCT I10A is being actively studied in II/III study; no studies for this drug have been completed so far.

 

Hepatocellular Carcinoma Pipeline Therapeutics Assessment

There are approx. 80+ key companies which are developing the therapies for Hepatocellular Carcinoma. The companies which have their Hepatocellular Carcinoma drug candidates in the most advanced stage, i.e. phase II/III include, Sinocelltech.

 

Find out more about the Hepatocellular Carcinoma Pipeline Segmentation, Therapeutics Assessment, and Hepatocellular Carcinoma Emerging Drugs @ Hepatocellular Carcinoma Treatment Landscape

 

Scope of the Hepatocellular Carcinoma Pipeline Report

 

  • Coverage- Global

 

  • Hepatocellular Carcinoma Companies- Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals,  Akeso Biopharma, Innovent Biologics, Eli Lilly and Company, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Jiangsu Hengrui Medicine, Shenogen Pharma, and others

 

  • Hepatocellular Carcinoma Therapies- lenvatinib, pembrolizumab (200 mg), Tivozanib, Durvalumab, Sorafenib, Enzalutamide, AZD9150, GC33 (RO5137382), mapatumumab, and others.

 

  • Hepatocellular Carcinoma Pipeline Segmentation: Product Type, Molecule Type, Mechanism of Action, Route of Administration 

 

Dive deep into rich insights for drugs for Hepatocellular Carcinoma Pipeline Companies and Therapies, click here @ Hepatocellular Carcinoma Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Hepatocellular Carcinoma Executive Summary
  3. Hepatocellular Carcinoma: Overview
  4. Hepatocellular Carcinoma Pipeline Therapeutics
  5. Hepatocellular Carcinoma Therapeutic Assessment
  6. Hepatocellular Carcinoma– DelveInsight’s Analytical Perspective
  7. Late Stage Products (Pre-Registration)
  8. Last Stage Products (Phase II/ III)
  9. SCT-I10A: Sinocelltech
  10. Mid Stage Products (Phase II)
  11. Preclinical and Discovery Stage Products
  12. Inactive Products
  13. Hepatocellular Carcinoma Key Companies
  14. Hepatocellular Carcinoma Key Products
  15. Hepatocellular Carcinoma – Unmet Needs
  16. Hepatocellular Carcinoma – Market Drivers and Barriers
  17. Hepatocellular Carcinoma – Future Perspectives and Conclusion
  18. Hepatocellular Carcinoma Analyst Views
  19. Hepatocellular Carcinoma Key Companies
  20. Appendix

 

Got Queries? Find out the related information on Hepatocellular Carcinoma Mergers and acquisitions, Hepatocellular Carcinoma Licensing Activities @ Hepatocellular Carcinoma Recent Trends, and Future Perspectives

 

 

About Us 

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/